By Deena Beasley

Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways, much the way the field of cancer therapeutics has been transformed in recent years, experts say.

Just two drugs are approved to slow Alzheimer’s – Eli Lilly’s Kisunla and Leqembi from Eisai and Biogen. Both were shown to delay disease ‍progression by around 30% by removing toxic amyloid plaques from the brain, but progress is being made to identify other targets and strategies for arresting the disease.

Globally, over 55 million people have dementia, with about 60% of those cases caused by Alzheimer’s, defined by the presence of amyloid and tau proteins in the

See Full Page